Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy
These data demonstrate the clinical safety profiles while ACT infusions with active COVID-19 infection.The intervention of ACT for cancer patients could generate the benefit for symptom alleviation with improved recovery time. The concurrent ACT for advanced cancer patients during such infectious pandemic might simultaneously leverage and reduce the risk of immune compromised situation for subsequent chemotherapy complications.
Authors
- Dazhao Xu (ORCID: https://orcid.org/0000-0002-4696-1881)
- H. Kim Lyerly (ORCID: https://orcid.org/0000-0002-0063-4770)
- Linyao Lu (ORCID: https://orcid.org/0000-0001-8849-6626)
- Peng Shu (ORCID: https://orcid.org/0000-0001-5611-5198)
- Chuxiong Zeng
- Michael A. Morse (ORCID: https://orcid.org/0000-0002-5725-4533)
- Congcong Li (ORCID: https://orcid.org/0000-0002-4459-5224)
- Li Liu (ORCID: https://orcid.org/0000-0003-2566-7357)
- Xiaoli Wang (ORCID: https://orcid.org/0000-0003-4569-5371)
- Haiyang Zhao (ORCID: https://orcid.org/0000-0003-4696-7391)
- Ping Lin (ORCID: https://orcid.org/0000-0003-3194-5595)
- Xianzhi Guo
- Jun Ren (ORCID: https://orcid.org/0000-0001-5399-000X)
- Zhenying Geng (ORCID: https://orcid.org/0009-0007-7433-124X)
- Amy Hobeika (ORCID: https://orcid.org/0009-0007-5701-9027)
- X.S. Rong
- Lina Hu
- Xinna Zhou
- Feifei Huo
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University (CN)
- Huadong Hospital (CN)
- Duke Medical Center (US)
- Pudong Medical Center (CN)
- Beijing Shijitan Hospital (CN)
Publication Details
- Journal
- Infectious Agents and Cancer
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1186/s13027-025-00654-2
- Citations
- 1
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Shanghai Pudong New Area Health Commission